Abu N.G.A. Khan, MD

Dr. Goldshtrom is a neonatologist who has additional training in pediatric cardiac intensive care. He works in both the neonatal intensive care unit as well as the infant cardiac unit caring for infants with congenital heart disease. The intensive care units at Columbia University Irving Medical Center (CUIMC) and Morgan Stanley Children's Hosiptal are regional referral centers for the sickest children and infants in the tri-state area. Our teams work in a multidisciplinary fashion utilizing expertise from surgeons, pediatric subspecialists, nutritionists, pharmacists, respiratory therapists as well as social workers, psychologists and case managers, to provide comprehensive patient centered care for each child and family.When not working clinically, he spends time working on clinical research projects centered around big data and non-invasive monitoring of critically ill neonates. Dr. Goldshtrom has interests in helping to bring data analytics to the bed side for intensive care to offer potential predictive tools for infants and children undergoing continuous monitoring for their conditions. He is also a founding board member of the neonatal heart society whose mission it is to bring experts and practioners together who care for infants with congenital heart disease to improve practices and outcomes.

Dr. Arcasoy was recruited to Columbia University as the Medical Program Director of Lung Transplantation in 2001 from the University of Pennsylvania. After his recruitment, he completely turned around the Lung Transplantation Program to rank amongst the top 5 to 10 programs in the country with regard to volume and patient survival. Under his leadership, the Lung Transplant Program has been performing more than 80 transplants annually. In October 2019, Dr. Arcasoy and his team celebrated their 1000th lung transplant since 2001. Despite high transplant volumes and very sick pretransplant candidates, the survival of lung transplant recipients has remained stellar. Currently, 1-year survival of lung transplant recipients at Columbia University is 90%, 5-year survival 65%, and 10-year survival 42%. Dr. Arcasoy has gained national and international reputation with various leadership roles in professional organizations and scientific societies. He previously chaired the Thoracic Organ Transplant Committee of the AST and the Transplant Network Steering Committee of the ACCP. He recently served in the Thoracic Organ Transplant Committee of the OPTN to develop Continuous Distribution of Lungs. He is currently the Associate Chair for Advanced Lung Failure and Transplantation in the Standards and Guidelines Committee of the ISHLT.